TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01840813
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a placebo group
Study: NCT01543919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT02128633
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
Study: NCT02128633
Drug: Fluoride neutral NaF gel 2 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: The product had similar appearance and viscosity than others.
Study: NCT01948973
Drug: Suprasensory
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stimulation is here set suprasensory
Study: NCT02532647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00367081
Drug: TMX-SMX (Bactrim(R))
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03929718
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive spironolactone treatment after CTI ablation
Study: NCT03929718
Drug: No Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no spironolactone treatment
Study: NCT04446312
Drug: Bowel Prep
Normalized name: Suprep Bowel Prep Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally ingested liquid bowel preparation
Study: NCT01082081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01163396
Drug: 5-fluorouracil/leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02662426
Drug: Lingdancao granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 packs per time (3g/pack), three times per day
Study: NCT02662426
Drug: analogous Lingdancao granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 packs per time, three times per day
Study: NCT01043744
Drug: Artemether-Lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)
Study: NCT01189344
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
Study: NCT01202890
Drug: Revlimid, Doxil, Avastin
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
Study: NCT02377414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
Study: NCT01218217
Drug: SQ109
Normalized name: SQ109
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ109 150 mg tablet
Study: NCT01539447
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
Study: NCT01539447
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
Study: NCT00936663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
Study: NCT00269113
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00918606
Drug: LIPO-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPO-102
Study: NCT00443703
Drug: MK0518 (raltegravir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
Study: NCT00443703
Drug: Comparator: KALETRA™ (lopinavir (+) ritonavir )
Approvals — FDA: no, EMA: no, PMDA: no
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
Study: NCT00443703
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Study: NCT00443703
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
Study: NCT05140772
Drug: Dipeptiven
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration daily for 7 days
Study: NCT01761214
Drug: Fluroquinolones
Approvals — FDA: no, EMA: no, PMDA: no
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
Study: NCT01761214
Drug: Beta-lactamase inhibitor
Normalized name: Beta-lactamase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
Study: NCT03636347
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily administration
Study: NCT05140772
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration daily for 7 days
Study: NCT00144209
Drug: levodopa in combination with benserazide
Normalized name: benserazide / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04317339
Drug: Zhigancao Tang placebo granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
Study: NCT02869321
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02869321
Drug: Fentanyl placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02155101
Drug: ART with 2 NRTIs plus LPV/r (or ATV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
Study: NCT01172444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository, Once Daily, Per Rectal for 6 Weeks
Study: NCT00666081
Drug: GSK690693
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
Study: NCT00014274
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03134391
Drug: Vapocoolant spray, EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
Study: NCT01986894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of Placebo
Study: NCT01957293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration
Study: NCT01309204
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo for masking purposes
Study: NCT02786212
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02026947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00078806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection twice a week
Study: NCT00110994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
Study: NCT06160401
Drug: Singletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singletine orally administered
Study: NCT06160401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally administered
Study: NCT02002702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02178800
Drug: GSK1265744 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg tablets, taken orally
Study: NCT02178800
Drug: Injectable GSK1265744
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection
Study: NCT02178800
Drug: Placebo for GSK1265744 Tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally
Study: NCT02178800
Drug: Injectable Placebo for GSK1265744
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection
Study: NCT03338400
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
Study: NCT01558284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04272567
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
Study: NCT04683406
Drug: ZSP1273 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 200-mg tablet taken orally
Study: NCT04683406
Drug: Placebo to ZSP1273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching ZSP1273 600 mg
Study: NCT02969265
Drug: TCV-116CCB
Normalized name: Typhoid conjugate vaccine (TCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116CCB Tablets
Study: NCT02969265
Drug: TCV-116CCB Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116CCB 8/5 mg placebo-matching tablets
Study: NCT04258462
Drug: Hyperpolarized 13C,15N2-urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03544905
Drug: CYH33 for tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
Study: NCT00602355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline.
Study: NCT03275090
Drug: Smoflipid ®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01789086
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
Study: NCT02872597
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
Study: NCT03723980
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
Study: NCT00735553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules orally daily for up to four months
Study: NCT04512001
Drug: MSB11456
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive MSB11456 subcutaneously, once a week.
Study: NCT01431898
Drug: Placebo to Match GS-9669 tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03101189
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule
Study: NCT02820844
Drug: GSK1358820
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
Study: NCT02820844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
Study: NCT02820844
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
Study: NCT05072054
Drug: Rosuvastatin Oral Tablet
Normalized name: rosuvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg
Study: NCT01101893
Drug: GSK2248761
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 200mg q24h x 5 days (Reference Treatment)
Study: NCT00804895
Drug: PROAMP, subcutaneous serum physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
Study: NCT02402530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered as intravenous infusion.
Study: NCT03400046
Drug: Nutritional Product Supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
Study: NCT00776542
Drug: Minocycline 100mg Tablets
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03040089
Drug: Neoquine Cream 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% hydroquinone cream
Study: NCT02176200
Drug: Berodual® Respimat®, low inspiratory flow rate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02176200
Drug: Berodual® Respimat®, medium inspiratory flow rate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02176200
Drug: Berodual® Respimat®, high inspiratory flow rate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02176200
Drug: Berodual® HFA-MDI, low inspiratory flow rate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02176200
Drug: Berodual® HFA-MDI, medium inspiratory flow rate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02176200
Drug: Berodual® HFA-MDI, high inspiratory flow rate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02340169
Drug: Topicort® (desoximetasone) Topical Spray, 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
Study: NCT02059564
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: doses of 6 mg, 16 mg
Study: NCT02059564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution
Study: NCT02826408
Drug: Pacebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparison to active treatment
Study: NCT01882387
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, 300mcg/kg/day for 28 days
Study: NCT00245453
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
Study: NCT00245453
Drug: telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg tablets; 2 tablets once daily (QD) for 5 days
Study: NCT00245453
Drug: Clarythromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg extended release tablets; 2 tablets QD for 7 days
Study: NCT01689987
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00648258
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks
Study: NCT00648258
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks
Study: NCT03599518
Drug: DS-1205c
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1205c 200 mg capsule for oral administration
Study: NCT01596712
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
Study: NCT01596712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
Study: NCT01658605
Drug: GSK1605786
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily administered orally
Study: NCT01527877
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed.
Study: NCT02517398
Drug: MSB0011359C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Study: NCT00429182
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Study: NCT00050102
Drug: MDX-010 (CTLA-4)
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04140786
Drug: Gentamicin Sulfate, Injectable
Normalized name: Gentamicin Sulfate, Injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
Study: NCT00364650
Drug: Probiotic Supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules twice daily
Study: NCT02781571
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg tablet administered orally once daily
Study: NCT01881282
Drug: Mayinglong Musk Hemorrhoid Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
Study: NCT01165125
Drug: FF / GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mcg/25mcg Novel DPI
Study: NCT02151656
Drug: F17464
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02151656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03420144
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
Study: NCT00006261
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
Study: NCT00006261
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT01607125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, orally, once daily for 13 to 14 days
Study: NCT03096327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
Study: NCT02065349
Drug: ASP8477
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02065349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral